GTJA Investment Group
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
China’s Harbour BioMed raises $103m Series C
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
Medical devices: Proceed with caution
Medical devices has become a difficult place to invest but potentially all the more rewarding for those willing to take the plunge. Asia is in a prime position globally
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.
GP profile: GTJA Investment Group
Having established itself as a leading player in the renminbi space, China healthcare sector specialist GTJA Investment Group now wants to prove its worth to overseas LPs
First responders: China VCs on a healthcare crisis
The coronavirus outbreak has thrust Chinese healthcare services into the spotlight, prompting investors to identify to sub-segments with potential for significant growth
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
China’s CF PharmTech raises $90m Series E
CF PharmTech, a Chinese devices maker focused on respiratory health, has raised $90 million in Series E funding led by local private equity investor New Alliance Capital.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Chinese online drug store Yao123 raises $45m Series B
Healthcare-focused GTJA Investment Group has led a RMB300 million ($45 million) Series B round for Chinese online pharmacy operator Yao123.
Deal focus: GTJA targets China online pharmacy boom
Healthcare specialist GTJA Investment Group leads a $130 million Series B for Jianke in the expectation that the company will consolidate its leadership position in China's online pharmacy market